In response to Fitch maintaining Hong Kong's AA- credit rating and stable outlook, the Hong Kong Special Administrative ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...

In related news, Singapore-based pharmaceutical company Mirxes, which specializes in cancer treatment, also had a strong debut in Hong Kong on the same day. The company’s shares rose by 28% in morning ...

Singapore-based cancer diagnostics firm MiRXES has listed on the Hong Kong Stock Exchange, with shares jumping 24.5% above the HKD 23.3 offer price on debut. The stock was trading at HKD 30 as of 3:00 ...

Theodore Shou, CEO of Yiyi Capital, discusses the recent strong performance of the IPO market in Hong Kong and says that the valuation premium between mainland China and Hong Kong stocks would narrow ...

The Chinese drugmaker raised HK$9.74 billion, equivalent to US$1.25 billion, in net proceeds, making it one of Hong Kong's largest IPOs so far this year. The stock was priced at HK$44.05 per share, ...

Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Robin Zeng’s high-stakes bets—from quitting his first job to founding CATL—have reshaped the global EV battery market.

The fintech firm is betting on global expansion and AI-driven financial infrastructure to anchor its next phase of growth.

Mod­er­na pulls BLA for its Covid-flu shot: The com­pa­ny sug­gest­ed on its most re­cent … Get free access to a limited ...

Ultra High Point, which aims to offer customized healthcare information-technology solutions and services to hospitals in Hong Kong, filed to go public in the U.S. The company said it plans to offer a ...

China hawks in Congress are pressuring executives at the financial giants JPMorgan Chase and Bank of America to back out of ...